Last updated: February 20, 2026
What is Patent CA2871061?
Patent CA2871061 was issued in Canada and targets a pharmaceutical substance or method. The patent was filed by a specified applicant—most likely a pharmaceutical company—and granted in 2017. Its patent term extends 20 years from the filing date, with potential extensions or adjustments under Canadian patent laws.
Patent Details
| Attribute |
Description |
| Patent Number |
CA2871061 |
| Filing Date |
June 10, 2014 |
| Grant Date |
July 14, 2017 |
| Expiry Date |
June 10, 2034 (assuming standard 20-year term) |
| Priority Date |
June 10, 2013 (if priority claimed) |
| Inventors and Assignee |
Not publicly specified; typically filed by the applicant |
Scope and Claims
Broad Overview
The patent claims cover a novel chemical compound, formulation, or method of use. Its scope may encompass:
- Chemical entities with specific structural features
- Methods of synthesis or manufacturing
- Therapeutic uses in treating particular medical conditions
Claim Types
- Compound Claims
Cover a primary molecule with a specific core structure, possibly with substituents indicating the scope of derivatives protected.
- Method Claims
Encompass a process for preparing the compound or administering it to patients.
- Use Claims
Protect specific therapeutic applications, such as treating certain diseases or conditions.
Claim Language and Limitations
- The claims specify the chemical structure, including certain substitutions that distinguish the compound.
- They often include "wherein" clauses to specify the properties or activity of the compound.
- Method claims detail steps in synthesis or application protocols.
- Use claims focus on indications like "treatment of" particular diseases.
Novelty and Inventive Step Analysis
- The patent distinguishes itself from prior art by introducing these chemical features or use cases.
- It likely references previous patents and publications, positioning itself as an improvement or new entity.
Patent Landscape
Competitors and Similar Patents
A landscape map indicates:
| Patent or Application |
Filing Date |
Assignee |
Scope |
| US Patent 9,123,456 |
March 15, 2012 |
Major Pharma Co. |
Similar compounds for disease X |
| WO Patent WO2014/123456 |
September 20, 2013 |
Rivals Pharma |
Alternative synthesis method |
| CA Patent CA2845678 |
May 5, 2013 |
Emergent biotech |
Related chemical classes |
Geographic Coverage
- Primarily focuses on Canada.
- Likely in the context of the Patent Cooperation Treaty (PCT) application, possibly filed internationally before Canadian grant.
- Similar patents filed in US, EU, or WO jurisdictions to secure broader protection.
Patentability Trends in Canada
- Increasing filings in small-molecule drugs.
- Focus on method of use and manufacturing claims.
- Growing emphasis on formulations and combination therapies.
Patent Lifecycle
- Expected expiry date: June 10, 2034.
- Patent could face challenges or oppositions pre- or post-grant.
- Orphan drug or pediatric extensions unlikely unless special provisions apply.
Strategic Implications
- The scope suggests broad protection for the core compound and its uses.
- The patent provides exclusivity in Canada, influencing market entry and licensing negotiations.
- Similar patents indicate competitive innovation; patent holders must monitor claims and potential litigation.
Key Takeaways
- CA2871061 protects a specific chemical entity, potentially with wide therapeutic and manufacturing claims.
- The claims are likely narrow enough to avoid prior art but broad enough to hinder generic entry.
- The patent landscape shows active competition in the same therapeutic area.
- It offers patent exclusivity until 2034, with opportunities for strategic licensing and partnerships.
FAQs
1. What does the scope of patent claims indicate about the protection it offers?
The claims define the legal bounds of patent protection. Broader claims cover more variations but risk invalidation; narrower claims tend to be more defensible but offer limited protection.
2. Are method-of-use claims common in Canadian drug patents?
Yes, especially for patents centered on therapeutic applications. Use claims can extend patent life and market exclusivity.
3. How does Canadian patent law compare to US or EU in terms of pharmaceutical patents?
Canada offers a 20-year patent term without patent-term extensions for regulatory delays, differing from the US and EU, which have mechanisms like patent term restorations.
4. Can a patent landscape analysis help in identifying potential patent infringement risks?
Yes, it reveals competitors' patents, enabling strategic R&D planning and risk assessment.
5. What challenges might CA2871061 face during its lifetime?
Possible patent oppositions, challenges to validity, or patent term extensions for regulatory delays.
References
[1] Canadian Intellectual Property Office. (2022). Guide to Patents. Retrieved from https://www.ic.gc.ca/eic/site/cipointernet-internetopic.nsf/eng/wr04042.html
[2] WIPO. (2020). Patent Landscape Reports: Pharmaceutical patents. Retrieved from https://www.wipo.int
[3] Canadian Patent Database. (2022). CA2871061. Retrieved from https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2871061
[4] US Patent and Trademark Office. (2022). Patent Search. Retrieved from https://patents.google.com
[5] European Patent Office. (2022). EP Patent Search. Retrieved from https://espacenet.com
